导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.61% | 3938/4773 |
| 近一周 | -1.98% | 1003/5462 |
| 近一月 | -1.62% | 986/5421 |
| 近一季 | -2.50% | 1251/5209 |
| 近半年 | -7.56% | 3231/4920 |
| 近一年 | -17.67% | 3846/4366 |
| 近两年 | 33.47% | 2146/2954 |
| 近三年 | 32.65% | 948/2253 |
| 成立以来 | 8.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.73% 4317/4961 |
-11.37% 4275/5312 |
- - |
- - |
| 2025 | 24.37% 1793/4813 |
17.87% 125/3635 |
1.89% 2039/4076 |
12.62% 3053/4524 |
-8.05% 3868/4813 |
| 2024 | 35.30% 59/3463 |
2.55% 755/2808 |
11.25% 31/3014 |
13.42% 2169/3129 |
4.56% 694/3463 |
| 2023 | -9.45% 1164/2656 |
0.85% 1685/2280 |
-0.38% 381/2385 |
-4.90% 1250/2515 |
-5.23% 1296/2655 |
| 2022 | -7.00% 134/2207 |
-9.33% 319/1919 |
8.45% 363/2016 |
-15.72% 1337/2113 |
12.21% 128/2208 |
| 2021 | -17.13% 1168/1822 |
3.35% 182/1255 |
-1.97% 1185/1330 |
-13.30% 1337/1466 |
-5.66% 1523/1822 |
| 2020 | -6.90% 980/1250 |
-13.13% 921/1028 |
2.64% 963/1067 |
-6.81% 1128/1164 |
12.04% 503/1184 |
| 2019 | 14.13% 700/1092 |
9.97% 723/739 |
-0.47% 261/788 |
-4.18% 762/850 |
8.82% 282/918 |
| 2018 | - - |
- - |
- - |
- - |
-8.60% 100/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝香港大盘C VS. 长安沪深300非周期A(740101) |